| 中文名称: | 阿糖腺苷 | ||||
|---|---|---|---|---|---|
| 英文名称: | Vidarabine | ||||
| 别名: | 腺嘌呤9-β-D-阿拉伯呋喃糖苷 Adenine 9-β-D-arabinofuranoside | ||||
| CAS No: | 5536-17-4 | 分子式: | C10H13N5O4 | 分子量: | 267.25 |
| CAS No: | 5536-17-4 | ||||
| 分子式: | C10H13N5O4 | ||||
| 分子量: | 267.25 | ||||
| MDL: | MFCD00065471 | EINEC: | 226-893-9 | ||
| EINEC: | 226-893-9 | ||||
包装规格：
1g 5g 25g in glass bottle
溶解性：
溶于DMF(10mg/mL)
产品描述：
一种核苷类抗生素，分离自链霉菌，能抗单纯性疱疹和水痘-带状疱疹病毒。
Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses. The drug was originally intended as an anti-cancer drug. The anti-viral activity of vidarabine was first described by M. Privat de Garilhe and J. De Rudder in 1964. It was the first nucleoside analog antiviral to be given systemically and was the first agent to be licensed for the treatment of systematic herpes virus infection in humans. It was University of Alabama at Birmingham researcher and physician Dr. Richard Whitley in 1976 where the clinical effectiveness of vidarabine was first realized, and vidarabine was used in the treatment of many viral diseases.
Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses. The drug was originally intended as an anti-cancer drug. The anti-viral activity of vidarabine was first described by M. Privat de Garilhe and J. De Rudder in 1964. It was the first nucleoside analog antiviral to be given systemically and was the first agent to be licensed for the treatment of systematic herpes virus infection in humans. It was University of Alabama at Birmingham researcher and physician Dr. Richard Whitley in 1976 where the clinical effectiveness of vidarabine was first realized, and vidarabine was used in the treatment of many viral diseases.
保存条件：
-20℃
UN码：
HazardClass：
危害声明：
安全说明：
搜索质检报告(COA)
参考文献 & 客户发表文献
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
